Compare Albertsons Companies Inc (ACI) vs ARK Genomic Revolution ETF (ARKG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albertsons Companies Inc vs ARK Genomic Revolution ETF — how do they compare? Albertsons Companies Inc trades at $12 (market cap $5.95B), while ARK Genomic Revolution ETF trades at $44.56. The key difference: Albertsons Companies Inc pays a 5.55% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Albertsons Companies Inc nearer its low. Which is the better fit depends on your goals.
| ACI | ARKG | |
|---|---|---|
Market Cap | $5.95B | — |
Sector | Consumer Staples | Sector/Thematic |
52-Week High | $19.74 | $44.55 |
52-Week Low | $11.03 | $24.02 |
Enterprise Value | $21.35B | — |
Dividend Yield | 5.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albertsons (ACI) trades at $11.98, down 1.24% with bearish technical signals despite recent insider buying by the CEO and CFO. The stock shows mixed fundamentals with strong revenue growth to $80.39B in 2025 but declining net margins to 0.08%. Recent Q2 2026 earnings missed expectations, triggering a 22% selloff and multiple legal investigations. Analyst consensus remains cautious with a $13.20 price target and 56.52% hold rating.
ACI presents a high-risk opportunity trading near multi-year lows with potential upside to analyst targets. Key catalysts include ACI Edge restructuring and digital initiatives, but investors face significant execution risks amid margin pressure and competitive grocery markets. The stock's deep value case is complicated by earnings volatility and ongoing legal scrutiny.
ARKG trades at $44.49, up 0.41% today, with a bullish technical bias from moving averages but overbought RSI signals. The ETF focuses on genomic revolution stocks, with top 10 holdings comprising 59% of assets and a long-term EPS growth rate of 10.7% (Seeking Alpha, 2026-07-28). Recent news highlights biotech sector strength driven by FDA friendliness and AI-driven drug discovery.
Outlook is cautiously optimistic given sector tailwinds, but high concentration and volatility pose risks. The ETF's exposure to small- and mid-cap biotech offers growth potential, yet investors face regulatory and market sentiment shifts. Near-term performance may hinge on broader tech trends and biotech M&A activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Albertsons Companies Inc
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Read more on ACI →About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →
